The Cell and Gene Therapy Access Model, which seeks to increase access to treatments for Medicaid enrollees with rare and severe diseases, will initially focus on sickle cell disease, the Centers for Medicare & Medicaid Services announced. The genetic blood disorder affects over 100,000 Americans, most of whom are Black and at least half of whom are enrolled in Medicaid. The model will begin in 2025.

“Gene therapies for sickle cell disease have the potential to treat this devastating condition and transform people’s lives, offering them a chance to live healthier and potentially avoid associated health issues,” said CMS Administrator Chiquita Brooks-LaSure. “Increasing access to these promising therapies will not only help keep people healthy, but it can also lead to savings for states and taxpayers as the long-term costs of treating sickle cell disease may be avoided.”

Related News Articles

Headline
A study published March 26 by the National Institutes of Health and the University of Oxford found that individuals who engaged in light and moderate-to-…
Headline
Sara Robinson, senior associate healthcare architect at McMillan Pazdan Smith Architecture, and Jamie Feinour, vice president of operations at Novant Health…
Headline
The Central Nevada Health District yesterday announced the state's first case of H5N1 bird flu, a dairy farm worker who was exposed to infected cattle. The…
Headline
The Centers for Disease Control and Prevention is following up on a previous alert of an outbreak of suspected fungal meningitis in Texas, which is now…
Headline
The U.S. Preventive Services Task Force yesterday released for public comment through June 5 a draft recommendation that all women get screened for breast…
Headline
In the latest podcast in AHA’s Advancing Health podcast series on leading initiatives to transform care and advance equity, leaders from Montage Health and…